袖状胃切除术会使癌症提前几十年出现（它"杀人"并让癌症提前到来）。
原始表述
لكن التكميم ده بيموت منه بقى اصلا فانت خليت السرطان ده لما يجي عند سن 550 سنه جه عند سن 55 سنه
按来源为原话. 译文由本项目提供；以阿拉伯语原文为准。
译文
袖状胃切除术会使癌症提前几十年出现（它"杀人"并让癌症提前到来）。
出处
- 来源状态
- 视频转录文本（本人原话）
- 归属
- Elawady (machine transcript)
- 视频
- Dr.D Clinics - Diaa Al Awady is live!التكميم (打开来源)
- 发布日期
- 2025年5月6日
- 时间戳
- 1:22:42 (在原视频 YouTube 自动字幕轨中的位置；可确认该内容出现的位置，但不能确认说话人是谁)
- 归属的不确定性
- Archive transcript (YouTube CC or AI-generated); wording may contain transcription errors; no timestamps available. The surrounding passage uses figurative ages (600, 550 years) in his theory of cancer as a 'defence plan'.
- 所声称的机制
Tissue damage from disturbed digestion accelerates cancer as a 'defence plan'.
- 所声称的健康影响
Earlier cancer.
- 涉及人群
Sleeve patients
- Elawady 设定的地域限制
none found
科学评估
基本错误 – 该说法的主要部分没有证据支持，或被严重夸大。
证据确定性: 中 – 进一步研究仍可能影响该评估。
1. 说法是什么？
That sleeve brings cancer forward.
2. 哪些内容可证实是正确的？
Long-term reflux and Barrett's after sleeve are documented (C-BAR-04), so a site-specific oesophageal risk is biologically plausible; in a French national cohort oesophageal cancer after sleeve was rare (about 4 per 100,000 person-years) and not significantly different from bypass (HR 1.60, 0.90-2.5; I-BAR-117). Nordic registry data show higher cancer mortality 15+ years after (mostly older) procedures (I-BAR-104).
3. 哪些内容是错误或夸大的？
Overall cancer incidence and cancer mortality were lower, not higher, after bariatric surgery: SOS cancer death HR 0.77 (A-BAR-05), Adams 60% lower cancer mortality (A-BAR-03), SOS 2007 cancer deaths 29 vs 47 (A-BAR-02), SPLENDID 10-year obesity-related cancer 2.9% vs 4.9% (I-BAR-118), upper GI cancer RR 0.58 and oesophageal cancer RR 0.63 (I-BAR-119). Nothing supports cancer appearing "decades earlier".
4. 哪些内容仍不明确？
Sleeve-specific long-term cancer data are limited.
5. 哪些研究支持该说法？
None directly. Limiting: I-BAR-104 (late cancer mortality HR 1.20, older procedures); I-BAR-117 (oesophageal cancer after sleeve vs bypass HR 1.60, not significant).
6. 哪些研究与该说法相矛盾？
7. 对德国和欧洲而言情况如何？
Most key data are European (Sweden SOS/SOReg, Finland SLEEVEPASS, Switzerland SM-BOSS). European and international society guidelines consider bariatric surgery for severe obesity with lifelong follow-up.
8. 关于埃及的已知情况是什么？
No Egypt-specific outcome data were identified in this review. Elawady states in a transcript that sleeve gastrectomy is very widely performed in Egypt ('مصر كلها بتعملها'); the procedure-specific risks (reflux, deficiencies) apply wherever it is performed, and follow-up quality (supplements, endoscopy, mental-health screening) determines part of the risk.
9. 合理的实际结论是什么？
没有证据表明袖状胃切除术会总体上导致癌症提前出现；术后总体癌症风险更低。应监测与反流相关的食管风险，术后仍应继续进行常规的癌症筛查。
评估详情
- 证据确定性的依据
Several large matched cohorts and meta-analyses consistently show lower cancer incidence and cancer mortality after bariatric surgery, including cohorts with many sleeve operations (SPLENDID I-BAR-118: obesity-related cancer aHR 0.68, cancer death aHR 0.52; I-BAR-102: sleeve cancer death HR 0.26 at 3 years) and specifically for oesophageal cancer (meta-analysis RR 0.63, I-BAR-119). Evidence is observational; a late cancer-mortality signal in Nordic registry data (HR 1.20 at >=15 years, mostly older procedures, I-BAR-104) and the long-term oesophageal risk after sleeve remain unresolved, hence not FALSE/high.
- 来源质量
Theory-based statement; no data cited.
- 地区可推广性
Applicable.
- 个体例外情况
Possible procedure-specific risks (e.g., oesophageal adenocarcinoma after long-term reflux) are not yet quantified.
- 说法的地域范围
- 普遍性（生物学/医学）
- 最近审核
- 2026年10月26日 初步
科学证据详解
已被科学证据否定 – 高质量证据显示情况恰恰相反，或该说法与已确立的生理学知识相矛盾。
研究问题: Does sleeve gastrectomy (or bariatric surgery) make cancer appear earlier or more often than in comparable people with obesity?
研究问题详解 (PICO)
- 人群
- Adults with obesity
- 干预或暴露
- Sleeve gastrectomy; bariatric surgery
- 对照
- Matched non-operated people with obesity; gastric bypass
- 地域范围
- universal biology
- 结局指标
- Cancer incidence (obesity-related, upper GI, oesophageal)
- Cancer mortality
研究结果按作者报告呈现。我们的评估见下文。
哪些证据支持该说法？
Nordic study: survival after obesity surgery
Kauppila et al.. Gastroenterology 2019 · PMID 30940524 · DOI 10.1053/j.gastro.2019.03.048 队列研究已核查摘要新增Nordic registry: cancer mortality lower overall but higher at >=15 years after surgery (mostly older procedures).
- 实际结果
- HR 0.84 overall; 1.20 (1.02-1.42) at >=15 y.
- 方法学质量
- moderate
- 相关性
- indirect (few sleeves)
- 局限
- Registry confounding
French national study: oesophageal cancer after sleeve vs bypass
Lazzati et al.. Surg Obes Relat Dis 2025 · PMID 39799019 · DOI 10.1016/j.soard.2024.12.002 队列研究已核查摘要新增French national cohort: oesophageal cancer after sleeve vs bypass not significantly different, point estimate higher.
- 实际结果
- HR 1.60 (0.90-2.5); 3.9/100,000 PY after SG.
- 方法学质量
- moderate
- 相关性
- direct for oesophageal cancer
- 局限
- Rare outcome
哪些证据不支持该说法？
US study: cancer after weight-loss surgery
SPLENDID: fewer obesity-related cancers and cancer deaths after surgery (one third sleeve).
- 实际结果
- aHR 0.68 (0.53-0.87); cancer death aHR 0.52 (0.31-0.88); 10-y 2.9% vs 4.9%.
- 方法学质量
- moderate
- 相关性
- direct
- 局限
- Single system
Meta-analysis: upper digestive cancers after weight-loss surgery
Meta-analysis: upper GI cancers, including oesophageal, less frequent after surgery.
- 实际结果
- RR 0.58; oesophageal RR 0.63 (0.40-0.98).
- 方法学质量
- moderate
- 相关性
- direct
- 局限
- Procedures mixed
Swedish 24-year study: surgery added about 3 years of life
SOS 24 years: cancer deaths lower after surgery.
- 实际结果
- HR 0.77 (0.61-0.96).
- 方法学质量
- moderate-high
- 相关性
- indirect (no sleeve)
- 局限
- Non-randomised
总体证据说明了什么？
基于上述研究的编辑评估——其本身并非研究结果。
哪种观点有更好的证据支持？
Cancer incidence and cancer mortality are lower, not higher, after bariatric surgery including cohorts with many sleeve operations; a possible small long-term oesophageal risk after sleeve is not excluded.
为什么有些研究权重更大
Several large matched cohorts and meta-analyses with consistent direction; sleeve-specific data (I-BAR-102 cancer death HR 0.26 at 3 y) included.
因果关系是否已确立？ 很可能 Consistent reduction with weight loss; observational.
仍存在的不确定性
Oesophageal adenocarcinoma after decades of sleeve-related reflux; late cancer-mortality signal in Nordic data.
合理的结论
The claim that sleeve brings cancer decades forward is not supported and is contradicted for cancer overall.
为什么研究结果看起来互相矛盾？
The late Nordic signal (HR 1.20 at >=15 y) concerns mostly older procedures and may reflect confounding; it does not match the claim of cancer decades earlier, and other cohorts show reductions.
这是否取决于国家？
- 一般生物学效应
- Universal.
- 饮食习惯
- Not applicable (surgical procedure, not a food).
- 食品原产地
- Not applicable (surgical procedure, not a food).
- 污染物
- Not applicable (surgical procedure, not a food).
- 本国生产条件
- Not applicable.
- 法律规则
- Not applicable.
- 实际监测数据
- No Egyptian data found.
足以改变结论的地区差异没有可靠数据支持。
统计复核
- Absolute risk reduction and NNT; CI symmetry – 10-y ARR 2.0% (NNT ~50) for obesity-related cancer; 0.6% (NNT ~167) for cancer death; CIs symmetric. 已重新计算
- Late cancer mortality HR CI – HR 1.20 (1.02-1.42) symmetric; lower bound close to 1. 已重新计算
总体证据的确定性（GRADE，简化版）
- 主要结局
- Cancer incidence/mortality after bariatric surgery vs obese controls
- 起始等级
- 低（观察性研究）
- 升级理由
- consistency across large cohorts and meta-analyses
- dose-response with weight loss (SPLENDID)
- 结果
- 中
由单名审查者参照 GRADE 方法进行的简化评估；并非正式的 GRADE 专家组评估。GRADE 评价的是针对某一结局的整体证据，而非单项研究。
检索策略
本次审查的文献检索记录（检索式采用原数据库语法）。
| 数据库 | 日期 | 检索式 | 检索目标 | 命中数 | 纳入数 |
|---|---|---|---|---|---|
| Europe PMC | 2026年10月26日 | (TITLE:"cancer") AND (TITLE:"bariatric surgery" OR TITLE:"sleeve gastrectomy" OR TITLE:"metabolic surgery") AND (TITLE:"incidence" OR TITLE:"risk") AND (PUB_TYPE:"Meta-Analysis" OR TITLE:"meta-analysis" OR TITLE:"cohort") AND PUB_YEAR:[2019 TO 2026] | 双向 | 35 | |
| PubMed | 2026年10月26日 | Aminian A[au] AND bariatric surgery AND obesity-associated cancer AND mortality AND JAMA[ta] | 反对性证据 | 1 | |
| Europe PMC | 2026年10月26日 | (TITLE:"esophageal adenocarcinoma" OR TITLE:"oesophageal adenocarcinoma" OR TITLE:"esophageal cancer" OR TITLE:"oesophageal cancer" OR TITLE:"esophagogastric cancer") AND (TITLE:"sleeve gastrectomy" OR TITLE:"bariatric" OR TITLE:"obesity surgery") | 双向 | 33 |
待解决的问题
Oesophageal adenocarcinoma incidence >20 years after sleeve.
核查深度如何？
10 项相关研究：3 项核查了全文（其中 0 项进行了结构化偏倚风险评估），7 项基于摘要核查，0 项仅核查了文献信息。 尚未进行由两名独立审查者完成的正式评估，也尚未进行独立的人类专家审核。
最近一次科学审核: 2026年10月26日
评定结论的变更历史
- 2026年10月25日 · 第 1 阶段 · 初始评估: 基本错误 (低)
- 2026年10月26日 · 第 4 阶段（系统证据审查） · 评定结论已更改: 基本错误 (低) → 基本错误 (中)
Verdict MOSTLY_FALSE kept; certainty raised from low to moderate because new large matched cohorts (I-BAR-118, I-BAR-102) and a 2025 meta-analysis (I-BAR-119) consistently show lower cancer incidence/mortality after surgery, including cohorts with many sleeve operations and specifically oesophageal cancer. MOSTLY_FALSE rather than FALSE because the long-term oesophageal risk after sleeve and a late Nordic cancer-mortality signal remain unresolved.
新来源: I-BAR-102 I-BAR-115 I-BAR-118 I-BAR-119 I-BAR-104 I-BAR-117
通俗解释
Elawady 声称，袖状胃切除术会使癌症提前很多出现。就总体癌症而言，大型研究发现的情况恰恰相反：与没有做手术的类似人群相比，减重手术后的癌症和癌症死亡更少，在许多患者做的是袖状胃切除术的研究中也是如此。袖状胃切除术后的食管癌很少见。袖状胃切除术后的长期反流是否会使这种癌症的风险略有升高，目前仍不清楚。
与该说法相关的研究
支持该说法的研究 (0)
该组中没有研究。
与该说法相矛盾或限制该说法的研究 (7)
-
Swedish study: fewer deaths after weight-loss surgery
Sjöström L et al.. N Engl J Med 2007 · PMID 17715408 · DOI 10.1056/NEJMoa066254队列研究被 Tayebat 档案网站引用已核查摘要Over about 11 years, people who had surgery had roughly 24-29% lower risk of dying than matched controls.
Sleeve gastrectomy makes cancer appear decades earlier (it 'kills' and brings cancer forward).
该研究是否支持这一具体说法？ 否 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Test mortality effect
- 研究是如何开展的？
Prospective matched study
- 研究了多少人、动物或样本？
4047 adults
- 实际发现了什么？
Fewer deaths after surgery
- 观察到的效应有多大？
Adjusted HR 0.71
- 研究结果对日常生活意味着什么？
Surgery was linked to living longer
- 该研究有哪些局限？
Not randomized; older techniques
- 它对 Elawady 的具体说法说明了什么？
Argues against 'surgery kills'
- 研究结果是否适用于德国和欧洲？
Directly European
- 从该研究中明确不能得出什么结论？
Exact causal size
-
Gastric bypass: fewer deaths overall, but more accident and suicide deaths
Adams TD et al.. N Engl J Med 2007 · PMID 17715409 · DOI 10.1056/NEJMoa066603队列研究被 Tayebat 档案网站引用已核查摘要★ 关键研究Total deaths were 40% lower after surgery, while deaths from accidents and suicide were higher (11.1 vs 6.4 per 10,000 person-years).
Sleeve gastrectomy makes cancer appear decades earlier (it 'kills' and brings cancer forward).
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Long-term mortality
- 研究是如何开展的？
Matched retrospective cohort
- 研究了多少人、动物或样本？
15,850 people
- 实际发现了什么？
Total deaths down, external-cause deaths up
- 观察到的效应有多大？
37.6 vs 57.1 total; 11.1 vs 6.4 non-disease per 10,000 PY
- 研究结果对日常生活意味着什么？
Net survival benefit with a specific mental health and accident risk
- 该研究有哪些局限？
Observational
- 它对 Elawady 的具体说法说明了什么？
Supports self-harm concern, contradicts 'lethal'
- 研究结果是否适用于德国和欧洲？
Comparable to Nordic findings
- 从该研究中明确不能得出什么结论？
Causation of suicide excess
-
Swedish 24-year study: surgery added about 3 years of life
Carlsson LMS et al.. N Engl J Med 2020 · PMID 33053284 · DOI 10.1056/NEJMoa2002449队列研究被 Tayebat 档案网站引用已核查全文★ 关键研究Operated patients lived about 3 years longer than non-operated patients with obesity, but still about 5.5 years less than the general population (non-operated: about 8.5 years less).
Sleeve gastrectomy makes cancer appear decades earlier (it 'kills' and brings cancer forward).
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Life expectancy
- 研究是如何开展的？
Prospective controlled cohort with population reference
- 研究了多少人、动物或样本？
5182 people
- 实际发现了什么？
Surgery gained 3 years; gap to population 5.5 vs 8.5 years
- 观察到的效应有多大？
HR death 0.77; +3.0 years
- 研究结果对日常生活意味着什么？
Surgery reduced but did not remove the life-expectancy loss linked to severe obesity
- 该研究有哪些局限？
Not randomized; old operations
- 它对 Elawady 的具体说法说明了什么？
Number correct, implication 'surgery shortens life' wrong
- 研究结果是否适用于德国和欧洲？
Directly European
- 从该研究中明确不能得出什么结论？
That surgery causes the remaining 5.5-year gap
-
US study: survival after sleeve and bypass
Courcoulas et al.. Ann Surg 2023 · PMID 34387200 · DOI 10.1097/SLA.0000000000005155队列研究独立交叉核查已核查全文★ 关键研究Over 5 years, people who had a sleeve died about 70% less often than similar people who did not have surgery (1.0% vs 2.7%).
Lower cancer-related mortality at 3 y after SG.
该研究是否支持这一具体说法？ 否 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Compare deaths after SG/RYGB with matched non-operated patients
- 研究是如何开展的？
Matched cohort, health records
- 研究了多少人、动物或样本？
13,900 SG; 17,258 RYGB; 87,965 controls
- 实际发现了什么？
Lower death rates after both operations
- 观察到的效应有多大？
SG HR 0.28 (0.13-0.57)
- 研究结果对日常生活意味着什么？
Sleeve was not associated with earlier death
- 该研究有哪些局限？
About one third lost to follow-up; observational
- 它对 Elawady 的具体说法说明了什么？
Contradicts "sleeve kills"
- 研究结果是否适用于德国和欧洲？
Plausible for Europe and Egypt
- 从该研究中明确不能得出什么结论？
Cannot exclude unmeasured confounding
-
Sleeve vs a weight-loss drug: Barrett changes
Butt et al.. Ann Gastroenterol 2026 · PMID 42164611 · DOI 10.20524/aog.2026.1058队列研究独立交叉核查已核查摘要Barrett changes were diagnosed in 0.3% after sleeve vs 0.1% with liraglutide; cancer did not differ.
No difference in oesophageal cancer.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 低 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Compare BE after SG vs liraglutide
- 研究是如何开展的？
Matched EHR cohort
- 研究了多少人、动物或样本？
20,096
- 实际发现了什么？
BE 0.3% vs 0.1%
- 观察到的效应有多大？
RR 2.70
- 研究结果对日常生活意味着什么？
Small absolute increase
- 该研究有哪些局限？
Detection bias
- 它对 Elawady 的具体说法说明了什么？
Supports a modest relative increase
- 研究结果是否适用于德国和欧洲？
US data
- 从该研究中明确不能得出什么结论？
Cancer risk
-
US study: cancer after weight-loss surgery
Aminian et al.. JAMA 2022 · PMID 35657620 · DOI 10.1001/jama.2022.9009队列研究独立交叉核查已核查全文★ 关键研究Over 10 years, obesity-related cancer occurred in 2.9% after surgery vs 4.9% without; cancer deaths 0.8% vs 1.4%.
Lower obesity-associated cancer (aHR 0.68) and cancer mortality (aHR 0.52).
该研究是否支持这一具体说法？ 否 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Cancer risk after surgery
- 研究是如何开展的？
Matched cohort
- 研究了多少人、动物或样本？
30,318
- 实际发现了什么？
Fewer cancers and cancer deaths
- 观察到的效应有多大？
aHR 0.68 and 0.52
- 研究结果对日常生活意味着什么？
Surgery was linked to less cancer, not more
- 该研究有哪些局限？
Observational, single system
- 它对 Elawady 的具体说法说明了什么？
Contradicts the claim
- 研究结果是否适用于德国和欧洲？
Plausible
- 从该研究中明确不能得出什么结论？
Sleeve-only long-term effect
-
Meta-analysis: upper digestive cancers after weight-loss surgery
Cooke et al.. BJS Open 2025 · PMID 41947341 · DOI 10.1093/bjsopen/zrag006Meta分析独立交叉核查已核查摘要★ 关键研究People who had surgery had about 40% fewer upper digestive cancers, including cancer of the gullet.
Upper GI cancer RR 0.58; oesophageal RR 0.63.
该研究是否支持这一具体说法？ 否 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Upper GI cancer after surgery
- 研究是如何开展的？
Meta-analysis
- 研究了多少人、动物或样本？
>5.7 million
- 实际发现了什么？
Lower risk
- 观察到的效应有多大？
RR 0.58
- 研究结果对日常生活意味着什么？
No sign of earlier cancer
- 该研究有哪些局限？
Observational, mixed procedures
- 它对 Elawady 的具体说法说明了什么？
Contradicts the claim
- 研究结果是否适用于德国和欧洲？
Applicable
- 从该研究中明确不能得出什么结论？
Sleeve-only data
该组中没有被标记为关键研究的研究。
结果不一或不明确的研究 (3)
-
Meta-analysis: Barrett's after sleeve
Chandan S et al.. Clin Gastroenterol Hepatol 2025 · PMID 39059544 · DOI 10.1016/j.cgh.2024.06.041Meta分析独立交叉核查已核查摘要★ 关键研究About 5.6% developed new Barrett's esophagus; reflux and acid-medication use were about 3 times more frequent after sleeve.
Sleeve gastrectomy makes cancer appear decades earlier (it 'kills' and brings cancer forward).
该研究是否支持这一具体说法？ 是 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
BE after SG
- 研究是如何开展的？
Meta-analysis
- 研究了多少人、动物或样本？
2046
- 实际发现了什么？
BE 5.6%; GERD x3
- 观察到的效应有多大？
RR GERD 3.32
- 研究结果对日常生活意味着什么？
Reflux is a major downside of sleeve
- 该研究有哪些局限？
Heterogeneous observational
- 它对 Elawady 的具体说法说明了什么？
Supports reflux/BE claim, not 'inevitable'
- 研究结果是否适用于德国和欧洲？
Applicable
- 从该研究中明确不能得出什么结论？
Cancer risk
-
Nordic study: survival after obesity surgery
Kauppila et al.. Gastroenterology 2019 · PMID 30940524 · DOI 10.1053/j.gastro.2019.03.048队列研究独立交叉核查已核查摘要★ 关键研究Operated people died less often than non-operated people with obesity, but more often than the general population; suicide deaths were more frequent.
Cancer mortality lower overall but HR 1.20 at >=15 y (mostly older procedures).
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Compare survival with two reference groups
- 研究是如何开展的？
Registry cohort
- 研究了多少人、动物或样本？
505,258 (49,977 operated)
- 实际发现了什么？
HR 0.63 vs obese; SMR 1.94 vs general population
- 观察到的效应有多大？
All-cause HR 0.63; suicide HR 1.68
- 研究结果对日常生活意味着什么？
Surgery reduces but does not remove the excess risk of obesity
- 该研究有哪些局限？
Older procedures; registry data
- 它对 Elawady 的具体说法说明了什么？
Contradicts "lethal", supports "still shorter life than general population"
- 研究结果是否适用于德国和欧洲？
Direct European data
- 从该研究中明确不能得出什么结论？
Sleeve-specific long-term effects
-
French national study: oesophageal cancer after sleeve vs bypass
Lazzati et al.. Surg Obes Relat Dis 2025 · PMID 39799019 · DOI 10.1016/j.soard.2024.12.002队列研究独立交叉核查已核查摘要★ 关键研究Oesophageal cancer was rare after both operations (about 4 per 100,000 per year after sleeve) and not significantly different.
Oesophageal cancer ~3.9/100,000 PY after SG; HR vs GB 1.60 (0.90-2.5).
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Compare cancer risk SG vs GB
- 研究是如何开展的？
National cohort
- 研究了多少人、动物或样本？
370,271
- 实际发现了什么？
No significant difference
- 观察到的效应有多大？
HR 1.60 (0.90-2.5)
- 研究结果对日常生活意味着什么？
Cancer of the gullet after sleeve is rare
- 该研究有哪些局限？
Coding; borderline result
- 它对 Elawady 的具体说法说明了什么？
Contradicts "cancer comes decades earlier"; leaves small uncertainty
- 研究结果是否适用于德国和欧洲？
Directly European
- 从该研究中明确不能得出什么结论？
Risk vs no surgery
该组中没有被标记为关键研究的研究。
地区背景
德国 / 欧盟
Most key data are European (Sweden SOS/SOReg, Finland SLEEVEPASS, Switzerland SM-BOSS). European and international society guidelines consider bariatric surgery for severe obesity with lifelong follow-up.
埃及
No Egypt-specific outcome data were identified in this review. Elawady states in a transcript that sleeve gastrectomy is very widely performed in Egypt ('مصر كلها بتعملها'); the procedure-specific risks (reflux, deficiencies) apply wherever it is performed, and follow-up quality (supplements, endoscopy, mental-health screening) determines part of the risk.
在我的国家适用什么？
一般科学评估
基本错误 按其表述是错误的：减重手术（包括袖状胃切除术）后癌症和癌症死亡更少；只有一个可能存在的轻微长期食管风险仍未解决。
该说法涉及生物学或医学关系。上述科学评估不论在哪个国家都适用；各国食品数据不会改变这一评估。
参考文献
- Effects of bariatric surgery on mortality in Swedish obese subjects.. Sjöström L et al.. N Engl J Med 2007 · PMID 17715408 · DOI 10.1056/NEJMoa066254
- Long-term mortality after gastric bypass surgery.. Adams TD et al.. N Engl J Med 2007 · PMID 17715409 · DOI 10.1056/NEJMoa066603
- Life Expectancy after Bariatric Surgery in the Swedish Obese Subjects Study.. Carlsson LMS et al.. N Engl J Med 2020 · PMID 33053284 · DOI 10.1056/NEJMoa2002449
- Reduction in Long-term Mortality After Sleeve Gastrectomy and Gastric Bypass Compared to Nonsurgical Patients With Severe Obesity.. Courcoulas et al.. Ann Surg 2023 · PMID 34387200 · DOI 10.1097/SLA.0000000000005155
- Incidence of Barrett's esophagus and esophageal cancer following sleeve gastrectomy versus liraglutide therapy.. Butt et al.. Ann Gastroenterol 2026 · PMID 42164611 · DOI 10.20524/aog.2026.1058
- Association of Bariatric Surgery With Cancer Risk and Mortality in Adults With Obesity.. Aminian et al.. JAMA 2022 · PMID 35657620 · DOI 10.1001/jama.2022.9009
- Upper gastrointestinal cancer risk following bariatric surgery: meta-analysis.. Cooke et al.. BJS Open 2025 · PMID 41947341 · DOI 10.1093/bjsopen/zrag006
- Risk of De Novo Barrett's Esophagus Post Sleeve Gastrectomy: A Systematic Review and Meta-Analysis of Studies With Long-Term Follow-Up.. Chandan S et al.. Clin Gastroenterol Hepatol 2025 · PMID 39059544 · DOI 10.1016/j.cgh.2024.06.041
- Effects of Obesity Surgery on Overall and Disease-Specific Mortality in a 5-Country Population-Based Study.. Kauppila et al.. Gastroenterology 2019 · PMID 30940524 · DOI 10.1053/j.gastro.2019.03.048
- Risk assessment for esophageal cancer after bariatric surgery: a comparative cohort study between sleeve gastrectomy and gastric bypass.. Lazzati et al.. Surg Obes Relat Dis 2025 · PMID 39799019 · DOI 10.1016/j.soard.2024.12.002